Literature DB >> 15116089

Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins.

Magdalena Koziczak1, Thomas Holbro, Nancy E Hynes.   

Abstract

Overexpression of fibroblast growth factor receptor (FGFR) tyrosine kinases has been found in many human breast cancers and has been associated with poor patient prognosis. In order to understand the mechanism by which FGFR mediates breast cancer cell proliferation, we used a low molecular weight compound, PD173074, that selectively inhibits FGFR tyrosine kinase activity and autophosphorylation. This potential anticancer agent caused a G1 growth arrest of MDA-MB-415, MDA-MB-453 and SUM 52 breast cancer cells. Our analyses revealed that FGFR signaling links to the cell cycle machinery via D-type cyclins. PD173074-mediated inhibition of FGFR activity caused downregulation of cyclin D1 and cyclin D2 expression, inhibition of cyclin D/cdk4 activity and, as a consequence, reduction of pRB phosphorylation. Retroviral-mediated ectopic expression of cyclin D1 prevented pRB hypophosphorylation and the cell cycle G1 block in PD173074-treated cells, suggesting a central role for D cyclins in proliferation of FGFR-driven breast cancer cells. The repression of FGFR activity caused downregulation of MAPK in MDA-MB-415 and MDA-MB-453 cells. In SUM 52 cells, both MAPK and PI3K signaling pathways were suppressed. In conclusion, results shown here describe a mechanism by which FGFR promotes proliferation of breast cancer cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15116089     DOI: 10.1038/sj.onc.1207331

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  62 in total

Review 1.  Adding to the mix: fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in non-small cell lung cancer.

Authors:  S A Kono; L E Heasley; R C Doebele; D R Camidge
Journal:  Curr Cancer Drug Targets       Date:  2012-02       Impact factor: 3.428

2.  Aryl Extensions of Thienopyrimidinones as Fibroblast Growth Factor Receptor 1 Kinase Inhibitors.

Authors:  Anil R Ekkati; Valsan Madiyan; Krishna P Ravindranathan; Jae H Bae; Joseph Schlessinger; William L Jorgensen
Journal:  Tetrahedron Lett       Date:  2011-04-27       Impact factor: 2.415

3.  A structure-guided approach to creating covalent FGFR inhibitors.

Authors:  Wenjun Zhou; Wooyoung Hur; Ultan McDermott; Amit Dutt; Wa Xian; Scott B Ficarro; Jianming Zhang; Sreenath V Sharma; Joan Brugge; Matthew Meyerson; Jeffrey Settleman; Nathanael S Gray
Journal:  Chem Biol       Date:  2010-03-26

4.  FGF and ERK signaling coordinately regulate mineralization-related genes and play essential roles in osteocyte differentiation.

Authors:  Ai Kyono; Nanthawan Avishai; Zhufeng Ouyang; Gary E Landreth; Shunichi Murakami
Journal:  J Bone Miner Metab       Date:  2011-06-17       Impact factor: 2.626

5.  FGFR1 Kinase Inhibitors: Close Regioisomers Adopt Divergent Binding Modes and Display Distinct Biophysical Signatures.

Authors:  Tobias Klein; Julie Tucker; Geoffrey A Holdgate; Richard A Norman; Alexander L Breeze
Journal:  ACS Med Chem Lett       Date:  2013-12-06       Impact factor: 4.345

6.  Signal transducers and activators of transcription-3 binding to the fibroblast growth factor receptor is activated by receptor amplification.

Authors:  Anna A Dudka; Steve M M Sweet; John K Heath
Journal:  Cancer Res       Date:  2010-04-13       Impact factor: 12.701

7.  Mammary tumorigenesis induced by fibroblast growth factor receptor 1 requires activation of the epidermal growth factor receptor.

Authors:  Lindsey K Bade; Jodi E Goldberg; Hazel A Dehut; Majken K Hall; Kathryn L Schwertfeger
Journal:  J Cell Sci       Date:  2011-08-24       Impact factor: 5.285

8.  Variation in the FGFR2 gene and the effect of a low-fat dietary pattern on invasive breast cancer.

Authors:  Ross L Prentice; Ying Huang; David A Hinds; Ulrike Peters; David R Cox; Erica Beilharz; Rowan T Chlebowski; Jacques E Rossouw; Bette Caan; Dennis G Ballinger
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-01       Impact factor: 4.254

9.  Differential fibroblast growth factor 8 (FGF8)-mediated autoregulation of its cognate receptors, Fgfr1 and Fgfr3, in neuronal cell lines.

Authors:  Natasha N Mott; Wilson C J Chung; Pei-San Tsai; Toni R Pak
Journal:  PLoS One       Date:  2010-04-12       Impact factor: 3.240

10.  Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-kappaB with antimyeloma activity in vitro and in vivo.

Authors:  Rodger E Tiedemann; Jessica Schmidt; Jonathan J Keats; Chang-Xin Shi; Yuan Xiao Zhu; Stephen E Palmer; Xinliang Mao; Aaron D Schimmer; A Keith Stewart
Journal:  Blood       Date:  2008-12-18       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.